CymaBay Therapeutics (CBAY) Stock Analysis
DELISTED 2024
What happened to CymaBay Therapeutics (CBAY) stock?
CymaBay Therapeutics (CBAY) no longer trades on public markets. It was delisted in March 2024. The figures below are historical and are not a current quote.
- Status:
- Delisted — no longer trades
- Delisting date:
- March 2024
- Last recorded price (historical):
- $32.48 (last quote on record before the March 2024 delisting; historical, not a current quote)
Market cap $3.73B is the value of all shares combined.
For informational purposes only. Not financial advice. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
CymaBay Therapeutics (CBAY). CymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases. Their lead product candidate, seladelpar, is in Phase III clinical study for primary biliary cholangitis (PBC).
Last analyzed: May 9, 2026CymaBay Therapeutics (CBAY) Healthcare & Pipeline Overview
More about this archive record
Can I still buy CBAY shares?
No. CBAY stopped trading on public markets in March 2024, so the shares are not available through a broker. Anything you see quoted for CBAY elsewhere is historical data, not a live market.
Are the figures on this page current?
No. Every number here is the last value recorded before CBAY stopped trading. Nothing on this page updates, and none of it is a current quote.
Why does this page still exist?
Because people still search for what happened to CymaBay Therapeutics. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.